MOST RECENT

COVID-19 Resources

Colorado COVID-19 Tracker

Discussion forum

Town Hall Webinars

Virtual Grand Rounds

CDPHE Contact Information

For local public health agencies and healthcare providers only:

  • From Monday thru Friday, 8:30 a.m.- 5:00 p.m., please call 303-692-2700.
  • For after-hours, holidays, and weekends, please call 303-370-9395.

For general questions about COVID-19:

  • Call CO-HELP at 303-389-1687 or 1-877-462-2911.
  • You can also email COHELP@RMPDC.org for answers in English.

Oral COVID-19 medication


The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.

The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.